2 results
Approved WMOCompleted
Compare Progression Free Survival (PFS) for brivanib versus placebo in subjects with advanced solid tumors with FGF-2 over-expression and who have obtained stable disease after 12 weeks of treatment with brivanib separately for each tumor.
Not approvedWill not start
The HemaTrate Blood Filtration System is commercially available and indicated for the rapid preparation of a TNC concentrate for use in human cell therapy applications. This study is designed to obtain the data needed to support a new, specific…